Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix Hexa vs Vaxelis in Infants
NCT04535037Phase 4Completed
- Sponsor
- GSK
- Start
- May 2021
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 4 trial of pertussis filamentous haemagglutinin in diphtheria, Tetanus, pertussis, hepatitis B (HBV), poliomyelitis, sponsored by GSK. Started May 2021; status: completed.
02
Drugs
pertussis filamentous haemagglutinin
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT04535037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535037.